Association Between Variants in Calcineurin Inhibitor Pharmacokinetic and Pharmacodynamic Genes and Renal Dysfunction in Adult Heart Transplant Recipients

Association Between Variants in Calcineurin Inhibitor Pharmacokinetic and Pharmacodynamic Genes and Renal Dysfunction in Adult Heart Transplant Recipients

Background: The goal of the study was to assess the relationship between single nucleotide variants (SNVs) in calcineurin inhibitor (CNI) pharmacokinetic and pharmacodynamic genes and renal dysfunction in adult heart transplant (HTx) recipients.Methods: This retrospective analysis included N = 192 p...

Full description

Bibliographic Details
Main Authors:	Kris Oreschak, Laura M. Saba, Nicholas Rafaels, Amrut V. Ambardekar, Kimberly M. Deininger, Robert L. Page, JoAnn Lindenfeld, Christina L. Aquilante
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-04-01
Series:	Frontiers in Genetics
Subjects:	renal dysfunction estimated glomerular filtration rate heart transplant pharmacogenetics pharmacogenomics calcineurin inhibitor
Online Access:	https://www.frontiersin.org/articles/10.3389/fgene.2021.658983/full

Similar Items

Pharmacokinetic and Pharmacodynamic Considerations in Relation to Calcineurin Usage in Elderly Kidney Transplant Recipients
by: Amelia R. Cossart, et al.
Published: (2021-04-01)

Polymorphisms in mTOR and Calcineurin Signaling Pathways Are Associated With Long-Term Clinical Outcomes in Kidney Transplant Recipients
by: Antony Brayan Campos-Salazar, et al.
Published: (2018-11-01)

Non-immunologic Actions of Calcineurin Inhibitors (CNIs) in Proteinuric Kidney Diseases
by: Robert Frank Spurney
Published: (2014-11-01)

INTEGRATING PHARMACOGENOMICS INTO CLINICAL PRACTICE
by: Gurinder Johal, et al.
Published: (2016-05-01)

Establishment of a Pharmacogenetics Service Focused on Optimizing Existing Pharmacogenetic Testing at a Large Academic Health Center
by: Amy L. Pasternak, et al.
Published: (2020-10-01)

Application of pharmacogenetics in oncology
by: Nelly N. Miteva-Marcheva, et al.
Published: (2020-08-01)

Calcineurin inhibitors and arterial hypertension in recipients of solid organs
by: E D Kosmacheva, et al.
Published: (2017-12-01)

Calcineurin inhibitors and arterial hypertension in recipients of solid organs
by: Kosmacheva E.D., et al.
Published: (2017-09-01)

Parents' and adolescents' access to and impressions of pharmacogenetic results viewed within a patient portal
by: Reardon, Meghann
Published: (2016)

The concept of gene is in crisis. Does it affect pharmacogenetics and pharmacogenomics?
by: Miriam Falkenberg, et al.
Published: (2006-09-01)

Personalization of the Immunosuppressive Treatment in Renal Transplant Recipients: The Great Challenge in “Omics” Medicine
by: Gianluigi Zaza, et al.
Published: (2015-02-01)

Variabilité d'origine génétique et épigénétique de la pharmacodynamie des inhibiteurs de la calcineurine en transplantation rénale
by: Pouche, Lucie
Published: (2016)

What Are the Barriers and Enablers to the Implementation of Pharmacogenetic Testing in Mental Health Care Settings?
by: Adam Jameson, et al.
Published: (2021-09-01)

by: Kathleen B Orrico
Published: (2019-12-01)

The Effects of Personal Pharmacogenetic Testing on the Effects of Pharmacy Student Perceptions of Knowledge and Attitudes Towards Precision Medicine
by: Dalga D Surofchy, PharmD (c), et al.
Published: (2017-01-01)

Decreased calcineurin immunoreactivity in the postmortem brain of a patient with schizophrenia who had been prescribed the calcineurin inhibitor, tacrolimus, for leukemia
by: Wada A, et al.
Published: (2016-07-01)

Pharmacogenetics and drug-induced nephrotoxicity in renal transplant recipients
by: Sepideh Zununi Vahed, et al.
Published: (2015-02-01)

Rationale and Design of the Genetic Contribution to Drug Induced Renal Injury (DIRECT) Study
by: Linda Awdishu, et al.
Published: (2016-11-01)

Genetic and Non-Genetic Factors Impact on INR Normalization in Preprocedural Warfarin Management
by: Eljilany I, et al.
Published: (2021-08-01)

Changes in ceftriaxone pharmacokinetics/pharmacodynamics during the early phase of sepsis: a prospective, experimental study in the rat
by: Valentina Selmi, et al.
Published: (2016-11-01)

Potential pharmacogenomic targets in bipolar disorder: considerations for current testing and the development of decision support tools to individualize treatment selection
by: Alfredo B. Cuéllar-Barboza, et al.
Published: (2020-07-01)

Pharmacogenomics of neuropathic pain
by: Vandana Sharma
Published: (2017-01-01)

Allele Drop Out Conferred by a Frequent CYP2D6 Genetic Variation For Commonly Used CYP2D6*3 Genotyping Assays
by: Giada Scantamburlo, et al.
Published: (2017-10-01)

An Interdisciplinary Experience focused on Pharmacogenetics: Engaging pharmacy and physician assistant students in conversations about antiplatelet therapy with respect to CYP2C19 genotype
by: Diane M Calinski, et al.
Published: (2016-02-01)

Personalized medicines – are pharmacists ready for the challenge?
by: Kennedy MJ
Published: (2018-09-01)

Tailor-made medicine: Is it practical?
by: Poornima Govindraju, et al.
Published: (2016-01-01)

GENETIC VARIABILITY OF PHARMACOKINETICS AND PHARMACODYNAMICS OF ANALGESICS (LAYERED MEDICINE)
by: Neamtu Monica, et al.
Published: (2019-09-01)

Invasive haemodynamics in de novo everolimus vs. calcineurin inhibitor heart transplant recipients
by: Niklas Bergh, et al.
Published: (2020-04-01)

An Integrated Transcriptomic Approach to Identify Molecular Markers of Calcineurin Inhibitor Nephrotoxicity in Pediatric Kidney Transplant Recipients
by: Erika T. Rhone, et al.
Published: (2021-05-01)

Introducing Pharmacogenetics and Personalized Medicine via a Weblog
by: Kaitlin Bova, et al.
Published: (2014-01-01)

Identification and mutational analyses of phosphorylation sites of the calcineurin-binding protein CbpA and the identification of domains required for calcineurin binding in Aspergillus fumigatus
by: Praveen Rao Juvvadi, et al.
Published: (2015-03-01)

Use of everolimus as an alternative to calcineurin inhibitors in renal allograft recipients: A single South Indian center's experience
by: Manns Manohar John, et al.
Published: (2019-01-01)

Pharmacogenetics Guidelines: Overview and Comparison of the DPWG, CPIC, CPNDS, and RNPGx Guidelines
by: Heshu Abdullah-Koolmees, et al.
Published: (2021-01-01)

Pharmacogenomics and Pharmacogenetics in Osteosarcoma: Translational Studies and Clinical Impact
by: Claudia Maria Hattinger, et al.
Published: (2020-06-01)

A Pharmacogenetically Guided Acenocoumarol Dosing Algorithm for Chilean Patients: A Discovery Cohort Study
by: Angela Roco, et al.
Published: (2020-04-01)

Precision Medicine: Emerging Trends in Cancer Therapy
by: Rahul Badwaik
Published: (2019-10-01)

Genetic variations in drug-induced liver injury (DILI): resolving the puzzle
by: Camilla eStephens, et al.
Published: (2012-11-01)

Renin‐angiotensin aldosterone profile before and after angiotensin‐converting enzyme‐inhibitor administration in dogs with angiotensin‐converting enzyme gene polymorphism
by: Darcy Adin, et al.
Published: (2020-03-01)

Clinical Application and Evaluation of Pharmacogenomics in Tumor Chemotherapy
by: Jifeng Feng
Published: (2014-03-01)

Web Resources for Pharmacogenomics
by: Guoqing Zhang, et al.
Published: (2015-02-01)